Antibody composition preparation and application thereof

A technology of antibody composition and preparation, which is applied in the direction of antibodies, drug combinations, anti-tumor drugs, etc., to achieve the effects of long-term storage, good tumor treatment activity, and prevention of content increase
CN102961745AActive Publication Date: 2013-03-13SUZHOU KANGJU BIOTECHNOLOGY CO LTD +1
2 Cites 20 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SUZHOU KANGJU BIOTECHNOLOGY CO LTD
Publication Date
2013-03-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Relating to the technical field of pharmaceutical preparations, the invention provides an antibody composition preparation composed of Trastuzumab and Pertuzumab. The antibody composition preparation has better tumor treatment activity. Compared with the independent treatment of Trastuzumab and Pertuzumab, the composition preparation shows a synergistic effect of the two antibodies, and can reach a tumor control rate of 92.43%. And the preparation provided in the invention has better stability, thus being in favor of long-term preservation of the antibody composition preparation. The antibody composition preparation provided in the invention is applicable to preparation of drugs treating diseases or symptoms suited to anti-HER2 antibody therapy. During application, the antibody composition preparation disclosed in the invention is used with a chemotherapeutic agent jointly or sequentially.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of pharmaceutical preparations, in particular to an antibody composition preparation formed by Trastuzumab Trastuzumab and Pertuzumab and an application thereof. Background technique

[0002] Human epidermal growth factor receptor 2 (Her-2) is a transmembrane sugar with receptor tyrosine kinase (receptortyrosine kinase, RTK) activity encoded by the proto-oncogene CerbB2 (Her2 / neu) protein. It belongs to the epidermal growth factor receptor family, which includes HER1 (erbB1, EGFR), HER2 (erbB2, NEU), HER3 (erbB3) and HER4 (erbB4). Studies have shown that Her-2 has gene amplification and protein overexpression in 20% to 30% of primary breast invasive ductal carcinomas. Her-2 positive breast cancer has strong invasiveness, short disease-free survival and poor prognosis. Trastuzumab Trastuzumab (trade name: Herceptin, herceptin) produced by Genentech, a subsidiary of Roche, is a humanized monoclonal antibody...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More